parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in müller glia	0.75
chemistry Open Targets	a small-molecule pocket	0.50
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 120	0.91
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 10726

SPON1 in dopamine neurons, braak-0.12 (p 0.767) → -0.34 (p 0.371)receipt 10734
SPON1 in astrocytes, braak-0.03 (p 0.946) → +0.02 (p 0.965)receipt 10733

receipt 10734: SPON1 in dopamine neurons, braak

power: full sample -0.23 (p 0.360, n 18), 95% CI -0.63 to +0.27. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.23 (p 0.360, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.37 (p 0.127, n 18). could be the mix.
skeptic: leave-one-out range -0.37 to -0.13, sign flips 0; without severely affected donors -0.23 (p 0.360, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SPON1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 10733: SPON1 in astrocytes, braak

power: full sample +0.03 (p 0.908, n 18), 95% CI -0.44 to +0.49. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.02 (p 0.942, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.14 (p 0.591, n 18). could be the mix.
skeptic: leave-one-out range -0.09 to +0.15, sign flips 4; without severely affected donors +0.03 (p 0.908, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SPON1 in astrocytes.

case closed: nothing better to follow up.

loading the receipts